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N-3 docosapentaenoic acid–derived resolvin D5 (RvD5n-3 DPA) is diurnally regulated in peripheral blood and exerts
tissue-protective actions during inflammatory arthritis. Here, using an orphan GPCR screening approach coupled with
functional readouts, we investigated the receptor(s) involved in mediating the leukocyte-directed actions of RvD5n-3 DPA
and identified GPR101 as the top candidate. RvD5n-3 DPA bound to GPR101 with high selectivity and stereospecificity, as
demonstrated by a calculated KD of approximately 6.9 nM. In macrophages, GPR101 knockdown limited the ability of
RvD5n-3 DPA to upregulate cyclic adenosine monophosphate, phagocytosis of bacteria, and efferocytosis. Inhibition of this
receptor in mouse and human leukocytes abrogated the pro-resolving actions of RvD5n-3 DPA, including the regulation of
bacterial phagocytosis in neutrophils. Knockdown of the receptor in vivo reversed the protective actions of RvD5n-3 DPA in
limiting joint and gut inflammation during inflammatory arthritis. Administration of RvD5n-3 DPA during E. coli–initiated
inflammation regulated neutrophil trafficking to the site of inflammation, increased bacterial phagocytosis by neutrophils
and macrophages, and accelerated the resolution of infectious inflammation. These in vivo protective actions of RvD5n-3
DPA were limited when Gpr101 was knocked down. Together, our findings demonstrate a fundamental role for GPR101 in
mediating the leukocyte-directed actions of RvD5n-3 DPA.
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Introduction
Development of the inflammatory response was a fundamental 
step in the evolution of multicellular organisms, given that this 
mechanism is vital in warding off invading pathogens and in coor-
dinating reparative and regenerative mechanisms (1, 2). Leuko-
cytes play a central role in the clearance of pathogens, in which, 
for example, neutrophils and macrophages are tasked with the 
uptake and killing of bacteria (3, 4). These cells are also important 
in coordinating the termination of acute inflammation as well as 
initiating tissue repair and regeneration (4–6). Central to the pro-
tective actions exerted by leukocytes is a novel genus of media-
tors termed specialized pro-resolving mediators (SPMs) (4, 7, 8). 
These autacoids are produced through the enzymatic conversion 
of essential fatty acids, which yields molecules with a defined ste-
reochemistry and potent biological properties (4, 7, 8).
Recent studies demonstrate that in addition to arachidonic 
acid, eicosapentaenoic acid, and docosahexaenoic acid (DHA), 
n-3 docosapentaenoic acid (n-3 DPA) is also a substrate for con-
version to novel, structurally distinct bioactive mediators (9, 
10). One of these novel mediators, n-3 DPA–derived resolvin 
D5 (RvD5n-3 DPA) (7S,17S-dihydroxy-8E,10Z,13Z,15E,19Z-docos-
apentaenoic acid), is diurnally regulated in human peripheral 
blood, and loss of its production, together with that of the related 
mediators RvD1n-3 DPA (7S,8R,17S-trihydroxy-9E,11E,13Z,15E,19Z- 
docosapentaenoic acid) and RvD2n-3 DPA (7S,16,17S-trihydroxy- 
8,10Z,12,14,19Z- docosapentaenoic acid), in patients with cardio-
vascular disease is linked with increased peripheral blood neu-
trophil, monocyte, and platelet activation (9). RvD5n-3 DPA also 
exerts tissue-protective actions by regulating mouse leukocyte 
trafficking and responses in vivo, as well as neutrophil, mono-
cyte, and macrophage responses in vitro (9). We recently uncov-
ered a homeostatic role for RvD5n-3 DPA in regulating intestinal 
epithelial barrier function, where decreased levels of this media-
tor during inflammatory arthritis are linked with increased intesti-
nal barrier permeability and joint inflammation (11). Treatment of 
arthritic mice with RvD5n-3 DPA restored barrier function, reduced 
leukocyte trafficking into the arthritic joints, and limited joint 
inflammation (11).
The biological actions of lipid mediators are stereospecific, 
suggesting that they activate cognate receptors to evoke down-
stream protective activities (12). Studies investigating the identity 
of these proteins demonstrate that lipid mediators, including 
the classic eicosanoids and SPMs, activate a class of receptors 
known as GPCRs (12, 13). In this context, the first pro-resolving 
mediator receptor identified was the lipoxin A4 receptor, also 
referred to as formyl peptide receptor 2 (ALX) or FPR2 (14). 
This receptor was later found to also mediate the biological 
actions of DHA-derived resolvin D1 (7S,8R,17S-trihydroxy- 
4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) as well as the 
pro-resolving protein annexin A1 (15, 16). Recent studies 
have uncovered a role for the orphan receptors GPR32 and 
GPR18 in mediating the biological actions of pro-resolving 
mediators, with RvD1 and RvD3 (4S,11R,17S-trihydroxy-5Z, 
7E,9E,13Z,15E,19Z-docosahexaenoic acid) activating GPR32 
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markedly reversed when these cells were preincubated with an 
anti-GPR101 antibody (Figure 2B).
We next investigated the stereospecificity of the interac-
tion between RvD5n-3 DPA and GPR101, assessing the capacity 
of related n-3 DPA–derived SPMs to activate this receptor. Incu-
bation of GPR101-expressing cells with either RvD1n-3 DPA or 
PD1n-3 DPA (10R,17S-dihydroxy-7Z,11E,13E,15Z,19Z-docosapenta-
enoic acid) did not elicit notable increases in chemilumines-
cent signals (Figure 2C), indicating a degree of selectivity for 
RvD5n-3 DPA. We made similar observations when assessing 
impedance changes, in which addition of RvD1n-3 DPA or PD1n-3 DPA 
to GPR101-expressing cells only elicited marginal changes in 
impedance (Figure 2D). To investigate the stereo specific nature 
of these receptor-ligand interactions, we next tested the ability 
of isopropyl-(7S,8E,15E,17S,19Z)-7,17-dihydroxydocosa-8,15,19- 
trien-10,13-diynoate (DA-RvD5n-3 DPA), an analog of RvD5n-3 DPA, 
to elicit changes in impedance. We found that substituting 
the double bond in the middle portion of the analog for triple 
bond, which would increase the rigidity of the molecule, led to 
a significant decrease in the ability of the molecule to activate 
the receptor (Figure 3, A and B). We further evaluated the ste-
reospecific nature of the interaction between RvD5n-3 DPA and 
GPR101 by assessing whether the DHA-derived RvD5 (7S,17S- 
dihydroxy-4Z,8E,10Z,13Z,15E,19Z-docosahexaenoic acid), which 
differs from the n-3 DPA congener by having an extra double bond 
on carbons 4 and 5, activates GPR101 to a similar degree. Using 
both impedance assays and the β-arrestin system, we found that 
RvD5 activated GPR101 to an extent similar to that seen with 
RvD5n-3 DPA, with a calculated EC50 of approximately 6.4 × 10
−14 M 
and approximately 9.7 × 10−13 M, respectively (Figure 3, C and D).
We next tested the role of G proteins in mediating the sig-
nals generated by RvD5n-3 DPA via the activation of GPR101. For 
this purpose, we incubated cells with either cholera toxin (CTX) 
(Gαs-like protein inhibitor) or pertussis toxin (PTX) (Gαi-like pro-
tein inhibitor) prior to addition of RvD5n-3 DPA. Incubation of cells 
with CTX, but not PTX, markedly inhibited the changes in imped-
ance elicited by RvD5n-3 DPA (Figure 3E). These results suggest that 
activation of GPR101 by RvD5n-3 DPA promotes the recruitment 
of Gαs-like proteins. Given that cAMP is the downstream second 
messenger of Gαs, we next investigated whether RvD5n-3 DPA upreg-
ulates cAMP in human monocyte–derived macrophages using an 
siRNA approach. Incubation of these cells with RvD5n-3 DPA led to 
an increase in cAMP concentrations (168 ± 56 pmol vs. 290 ± 98 
pmol per 0.4 × 106 cells), an increase that was absent in cells trans-
fected with an siRNA against GPR101 (Figure 3F).
Binding of 3H-RvD5n-3 DPA to GPR101. Next, we determined the 
affinity of the ligand-receptor interaction. For this purpose, we 
prepared tritium-labeled RvD5n-3 DPA by catalytic tritiation with 
a specific activity of approximately 40 Ci/mmol. The purity and 
integrity of the tritiated product were determined using reversed-
phase ultraviolet HPLC (RP-UV-HPLC) to be approximately 95%, 
as demonstrated by essentially identical retention times between 
the authentic RvD5n-3 DPA and [10, 11, 13, 14
3H]-RvD5n-3 DPA as well 
as matching UV chromophores with an UV absorbance maximum 
in ethanol (λmax
ETOH) of 245 nm (Figure 4A). Furthermore, quan-
tification of radioactivity demonstrated that approximately 98% 
of the activity was associated with [10, 11, 13, 143H]-RvD5n-3 DPA, 
(16, 17) and RvD2 activating GPR18 (18). Of note, the identity 
of the receptor mediating the biological actions of RvD5n-3 DPA 
is not known.
In the present study, we used an integrated approach to estab-
lish the identity of the GPCR that mediates the pro-resolving 
actions of RvD5n-3 DPA on leukocytes. Results from these experiments 
identified GPR101 as a candidate receptor for RvD5n-3 DPA. Flow 
cytometric analysis demonstrated that GPR101 was expressed on 
both human and mouse peripheral blood leukocytes. Using radio-
labeled RvD5n-3 DPA, we observed specific binding of this media-
tor to GPR101 with an affinity that was within its bioactive range. 
Knockdown of Gpr101 in mice led to an abrogation of the protective 
actions of RvD5n-3 DPA in vivo by limiting its ability to regulate inflam-
matory arthritis and infectious inflammation.
Results
Identification of candidate receptors for RvD5n-3 DPA. In order to 
establish whether the biological actions of RvD5n-3 DPA were 
mediated by a GPCR, we screened a panel of orphan GPCRs to 
determine whether RvD5n-3 DPA showed agonistic activity toward 
these receptors, using 10 nM RvD5n-3 DPA and assessing increases 
in luminescence as a readout for receptor activation. Here, we 
found that the strongest agonistic signals elicited by this pro- 
resolving mediator were with GPR101, GPR12, and GPR84 (Fig-
ure 1A), with values approximately 15%–20% above the control 
value. Given that RvD5n-3 DPA regulates the biological actions of 
monocyte-derived macrophages and peripheral blood leuko-
cytes (9, 10), we next investigated the expression of these 3 
receptors on circulating human neutrophils and monocytes and 
identified all 3 receptors (Figure 1B). Moreover, human mono-
cyte–derived macrophages also expressed all 3 receptors on their 
cell surface (Figure 1C).
RvD5n-3 DPA stereospecifically activates GPR101. To establish 
the role of these receptors in mediating the biological actions 
of RvD5n-3 DPA, we evaluated the ability of this ligand to activate 
each of these 3 receptors using a β-arrestin–based ligand recep-
tor interaction screening system, which enabled the construction 
of full dose-response curves (19). In these settings, RvD5n-3 DPA 
increased chemiluminescence in a concentration-dependent 
manner in cells overexpressing GPR101, with a calculated EC50 
of 4.6 × 10–12 M (Figure 2A). Of note, this increase in chemilumi-
nescence was not observed in cells expressing either GPR12 or 
GPR84 (Figure 2A). Using the β-arrestin system, we also tested 
whether RvD5n-3 DPA activates the pro-resolving receptors GPR32 
(also known as DRV1) and GPR18 (also known as DRV2). Here, 
we found that RvD5n-3 DPA displayed an affinity for GPR32/DRV1 
comparable to that observed with RvD1, with an EC50 of approxi-
mately 1.4 × 10−11 M and approximately 1.5 × 10−12 M, respec tively. 
Of note, RvD5n-3 DPA did not appear to activate GPR18/DRV2 at 
bio logically relevant concentrations (Supplemental Figure 1; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI131609DS1).
Given that GPCR activation leads to changes in both cell 
shape and size (20), we next used an impedance-based assay to 
further evaluate the interactions between RvD5n-3 DPA and GPR101. 
We found that incubation of RvD5n-3 DPA with GPR101-expressing 
CHO cells led to changes in impedance, an observation that was 
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Figure 1. RvD5n-3 DPA receptor candidates are expressed on human leukocytes. (A) Activation of orphan receptors by RvD5n-3 DPA (10 nM). Results represent 
the percentage increase in luminescence signal over vehicle control. (B and C) Expression of the top 3 candidate receptors on human (B) peripheral blood 
leukocytes and (C) macrophages. Results are representative of 4 donors. FSC, forward scatter; SSC, side scatter.
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rophages with RvD5n-3 DPA led to a dose-dependent increase in 
efferocytosis of pHrodo Red–labeled apoptotic cells. Meanwhile, 
transfection of macrophages with an siRNA against GPR101 
limited the ability of RvD5n-3 DPA to upregulate efferocytosis in a 
similar manner (Figure 5, D and E).
We recently found that RvD5n-3 DPA upregulates the activity of 
indoleamine 2,3-dioxygenase (IDO) in macrophages (11), which 
metabolizes tryptophan to l-kynurenine, a mechanism implicated 
in upregulation of the homeostatic IL-10 receptor (IL-10R) (22). 
Therefore, we tested the role of GPR101 in mediating the upregu-
lation of l-kynurenine concentrations by monocyte-derived macro-
phages. In line with published findings, we observed that incubation 
of control siRNA–transfected macrophages with RvD5n-3 DPA led to 
an upregulation of l-kynurenine concentrations, whereas addition 
of this mediator to cells transfected with an siRNA against GPR101 
only marginally regulated the concentrations of this metabolite 
(Figure 5F). Together, these findings demonstrate a nonredundant 
role for GPR101 in mediating the biological actions of RvD5n-3 DPA on 
human monocyte–derived macrophages.
GPR101 mediates the protective actions of RvD5n-3 DPA on neu-
trophils and monocytes. Since RvD5n-3 DPA regulates the biological 
actions of neutrophils (9, 10, 23) and GPR101 is expressed on 
these cells (Figure 1), we complemented the results produced with 
human monocyte–derived macrophages by determining the neu-
trophil-directed actions of RvD5n-3 DPA. Incubation of RvD5n-3 DPA 
with human neutrophils led to a significant and dose-dependent 
reduction in both the rate of neutrophil migration toward leuko-
triene B4 (LTB4) and the total number of cells migrated (Figure 6, 
A–C). In addition, RvD5n-3 DPA also reduced the number of cells that 
transmigrated through an activated endothelial cell mono layer 
under flow conditions (Figure 6D). Incubation of neutrophils to 
an antibody targeting GPR101 reversed the biological actions of 
given that the peak in activity coincided with the eluting of the 
molecule (Figure 4B). We next conducted saturation binding stud-
ies to establish the KD for binding of RvD5n-3 DPA to GPR101. These 
experiments yielded a calculated KD of approximately 6.9 nM (Fig-
ure 4C). To determine the specificity of the RvD5n-3 DPA-GPR101 
interaction, we next sought to establish the IC50 of the interaction. 
We found that RvD5n-3 DPA and [10, 11, 13, 14
3H]-RvD5n-3 DPA com-
peted for GPR101 binding, with an IC50 of approximately 9.3 nM 
(Figure 4D). Together, these results demonstrate that the affinity 
of RvD5n-3 DPA for GPR101 was within the bioactive range for this 
mediator (9, 10).
GPR101 mediates the regulatory actions of RvD5n-3 DPA on macro-
phages. In order to test the functional role of GPR101 in mediat-
ing the pro-resolving actions of RvD5n-3 DPA in human monocyte–
derived macrophages, we next knocked down the expression of 
this receptor using siRNA. Given the central role of macrophages 
in promoting the resolution of bacterial infections via the uptake 
and killing of pathogens in a process termed phagocytosis (4, 7, 18), 
we next investigated whether RvD5n-3 DPA regulates phagocytosis of 
bacterial particles in a GPR101-dependent manner. For this pur-
pose, we used pHrodo Green–conjugated Staphylococcus aureus 
(S. aureus) bioparticles that become increasingly fluorescent as 
pH decreases, thus providing a readout of phagocytic uptake and 
subsequent phagolysosomal degradation of ingested material. 
Incubation of scrambled control siRNA–transfected macrophages 
with RvD5n-3 DPA led to a dose-dependent increase in phagocyto-
sis. Transfection of macrophages with an siRNA against GPR101, 
which significantly reduced receptor expression, abrogated the 
ability of RvD5n-3 DPA to upregulate phagocytosis (Figure 5, A–C).
Next, we tested the ability of these macrophages to take up 
apoptotic cells, a key pro-resolving action termed efferocytosis 
(4, 6, 12, 16, 21). Treatment of control siRNA–transfected mac-
Figure 2. Activation of GPR101 by RvD5n-3 DPA. (A) RvD5n-3 DPA  
was incubated at the indicated concentrations with CHO 
cells expressing human GPR101 (circles), GPR84 (squares), 
or GPR12 (triangles) coupled with the β-arrestin reporter 
system, and receptor activation was measured as an increase 
in luminescence signal. Results represent the mean ± SEM. 
n = 5–7 independent experiments. *P < 0.05, **P < 0.01, and 
***P < 0.001 versus the respective vehicle control group; 
2-way ANOVA with Tukey’s post hoc multiple comparisons 
test. (B) CHO cells overexpressing GPR101 were incubated 
with either isotype control or anti-GPR101 antibody (30 
minutes at room temperature) and then with 1 nM RvD5n-3 DPA, 
and impedance was measured over a 20-minute period using 
the xCELLigence DP system. Results are representative of 3 
distinct experiments. (C) CHO cells expressing GPR101 coupled 
with the β-arrestin reporter system were incubated with the 
indicated concentrations of RvD5n-3 DPA, RvD1n-3 DPA, PD1n-3 DPA, 
or vehicle (PBS containing 0.01% ethanol), and receptor acti-
vation was measured as an increase in luminescence signal. 
Results represent the mean ± SEM. n = 5–7 independent 
experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 versus 
the vehicle control group; 2-way ANOVA with Tukey’s post 
hoc multiple comparisons test. (D) RvD5n-3 DPA, RvD1n-3 DPA, and 
PD1n-3 DPA (10 nM) were incubated with GPR101-expressing CHO 
cells, and impedance was measured over a 30-minute period 
using the xCELLigence DP system. Results are representative 
of 3 distinct experiments.
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these findings establish a role for GPR101 in mediating the biolog-
ical actions of RvD5n-3 DPA on neutrophils and monocytes.
GPR101 mediates the antiarthritic actions of RvD5n-3 DPA. 
RvD5n-3 DPA displays potent antiarthritic actions that regulate both 
neutrophil and macrophage responses in inflammatory arthritis 
(11). Thus, we next investigated the role of GPR101 in mediat-
ing these protective actions. For this purpose, we treated mice 
with either an siRNA targeting mouse Gpr101 to knock down 
the expression of this receptor in vivo, or a control sequence. 
We then challenged the mice with arthritogenic serum from K/
BxN mice, which initiates a polyarthritic disease driven by both 
monocytes and neutrophils (24). Assessment of clinical scores 
revealed that treatment of mice transfected with a control siRNA 
sequence with RvD5n-3 DPA led to a significant reduction in clin-
ical scores when compared with vehicle-treated mice (5.5 ± 1.8 
in RvD5n-3 DPA–treated mice vs. 9.0 ± 0.5 in mice given vehicle), 
RvD5n-3 DPA, increasing both neutrophil chemotaxis and transmi-
gration (Figure 6, A–D).
Since neutrophils are pivotal for the clearance of bacterial 
infections (3, 4), we next tested whether RvD5n-3 DPA, via GPR101, 
increases the ability of these cells to take up bacteria. Flow cyto-
metric assessment of peripheral blood neutrophils and monocytes 
demonstrated that these cells expressed the murine ortholog of 
human GPR101 (Supplemental Figure 2). Incubation of whole 
blood from mice transfected with a control siRNA sequence with 
RvD5n-3 DPA led to a significant increase in bacterial phagocyto-
sis by both neutrophils (643 ± 96 vs. 1886 ± 154 MFI units) and 
monocytes (1280 ± 97 vs. 3418 ± 208 MFI units). These actions 
were reversed when the mediator was added to peripheral blood 
collected from mice transfected with siRNA against Gpr101 that 
reduced the expression of the receptor on peripheral blood leu-
kocytes (Figure 6, E and F, and Supplemental Figure 3). Together, 
Figure 3. RvD5n-3 DPA stereospecifically acti-
vates GPR101 and increases cAMP in human 
macrophages. (A) GPR101-expressing CHO cells 
were incubated with RvD5n-3 DPA or DA-RvD5n-3 DPA 
(10 nM), and impedance was measured for 30 
minutes. Results are representative of 3 distinct 
experiments. (B) GPR101-expressing CHO cells 
were incubated with the indicated concentrations 
of the ligands described in A, and changes in 
impedance from baseline values were deter-
mined at t = 10 minutes. Results represent the 
mean ± SEM. n = 3 from 3 distinct experiments. 
*P < 0.05; 1-way ANOVA with a Holm-Sidak post 
hoc multiple comparisons test. (C) GPR101-over-
expressing CHO cells were incubated with 
RvD5n-3 DPA or DHA-derived RvD5 (1 nM), and cell 
impedance was measured over a 30-minute 
period using the xCELLigence DP system. Results 
are shown as the mean ± SEM (n = 4 in 3 inde-
pendent experiments). (D) CHO cells expressing 
GPR101 coupled with the β-arrestin luminescence 
reporter system were incubated with the indi-
cated concentrations of RvD5n-3 DPA, DHA-derived 
RvD5, or vehicle (cell-plating reagent containing 
0.01% ethanol), and receptor activation was 
measured as an increase in luminescence signal. 
Results are shown as the mean ± SEM (n = 3 in 2 
independent experiments). (E) GPR101-express-
ing CHO cells were incubated with CTX (1 μg/mL, 
2 hours), PTX (1 μg/mL, 16 hours), or vehicle and 
then with RvD5n-3 DPA (10 nM), and impedance 
was measured over a 30-minute period. Results 
are representative of 3 distinct experiments. 
(F) Human monocyte–derived macrophages 
were incubated with either an siRNA against 
GPR101 or a control sequence (CT siRNA; 72 
hours at 37°C) and then with RvD5n-3 DPA (10 nM) 
or vehicle (Veh) (PBS containing 0.01% ethanol) 
for 2 minutes, and cAMP concentrations were 
assessed. Results represent the mean ± SEM (n = 
4 donors). *P < 0.05; 1-way ANOVA with Holm- 
Sidak post hoc multiple comparisons test.
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whereas in mice transfected with an siRNA against Gpr101, 
this antiarthritic activity of RvD5n-3 DPA was lost (9.5 ± 0.3 in 
RvD5n-3 DPA –treated mice vs. 10.5 ± 1.7 in mice given vehicle) 
(Figure 7, A and B). Transfection of mice with an siRNA against 
Gpr101 diminished the ability of this mediator to protect against 
weight loss (a marker of disease severity), limit joint edema, and 
reduce joint concentrations of the inflammation-initiating pros-
taglandins and LTB4 (Figure 7, C–F).
We recently found that inflammatory arthritis disrupts 
gut barrier function, which promotes joint inflammation (11). 
RvD5n-3 DPA administration reduced intestinal inflammation 
and eicosanoid concentrations and upregulated intestinal pro- 
resolving mediator levels (11). Therefore, in this study, we 
assessed whether GPR101 was central to these modulatory 
properties of RvD5n-3 DPA. Lipid mediator profiling of intestinal 
tissues demonstrated that in mice administered a control siRNA 
sequence, RvD5n-3 DPA reduced the concentrations of the inflam-
matory eicosanoids, including PGD2 (193.4 ± 38.9 in vehicle- 
treated mice vs. 95.0 ± 15.7 pg/50 mg tissue) and PGE2 (376.3 
± 58.3 in vehicle-treated mice vs. 177.8 ± 16.9 pg/50 mg tissue), 
and increased the concentrations of select SPMs, namely RvD4 
(0.6 ± 0.24 in vehicle-treated-mice vs. 2.7 ± 0.3 pg/50 mg tis-
Figure 4. Specific binding of [3H]-RvD5n-3 DPA to human GPR101. (A and B) Characterization of [10, 11, 13, 14 3H]-RvD5n-3 DPA ([3H]-RvD5n-3 DPA). (A) RP-UV-
HPLC chromatogram for RvD5n-3 DPA and [
3H]-RvD5n-3 DPA. (B) RP-UV-HPLC chromatogram of [3H]-RvD5n-3 DPA and online radioactivity monitoring. (C) 
GPR101-overexpressing CHO cells (0.5 × 106 cells in 100 μL) were incubated with [3H]-RvD5n-3 DPA at the indicated concentrations in the presence or 
absence of 10 μM RvD5n-3 DPA (60 minutes at 4°C). Cell incubations were transferred to a vacuum manifold, unbound radioligand was removed, and 
activity was measured. Results represent the mean ± SEM (n = 4 from 2 distinct experiments). Inset shows a Scatchard plot. (D) To assess competition 
binding, GPR101-expressing CHO cells (0.5 × 106 cells in 100 μL) were incubated with 3 nM [3H]-RvD5n-3 DPA in the presence or absence of increasing concen-
trations of RvD5n-3 DPA for 60 minutes at 4°C.
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sue) and 17R-RvD1 (0.0 ± 0.0 in vehicle-treated mice vs. 0.21 
± 0.05 pg/50 mg tissue). Of note, these protective actions were 
diminished in mice transfected with the siRNA against Gpr101 
prior to RvD5n-3 DPA administration (Supplemental Figure 4).
RvD5n-3 DPA accelerates the resolution of bacterial infections via 
GPR101. Having established that RvD5n-3 DPA increased the abil-
ity of monocytes, macrophages, and neutrophils to take up bac-
teria, we next questioned whether this mediator was produced 
during bacterial infections and whether its production was tem-
porally regulated during self-limited infections. For this purpose, 
we inoculated mice with E. coli and assessed the temporal pro-
duction of RvD5n-3 DPA using lipid mediator profiling. This anal-
ysis demonstrated that RvD5n-3 DPA was produced during bacte-
rial infections, with its production reaching a maximum at the 
12-hour interval and remaining sustained into the resolution 
phase of the inflammatory response (Figure 8A). We next tested 
whether the protective actions of RvD5n-3 DPA in promoting bac-
terial clearance as observed in vitro were retained in vivo and 
examined the role of GPR101 in mediating the observed regula-
tory actions. In mice given a control siRNA sequence, adminis-
Figure 5. GPR101 mediates the 
protective actions of RvD5n-3 DPA 
on human macrophages. (A) 
Human monocyte–derived 
macrophages were incubated 
with either an siRNA against 
GPR101 or a control sequence 
(CT siRNA) for 96 hours, and  
GPR101 expression was 
assessed using flow cytometry 
(n = 4 donors). (B) Cells were 
transfected as in A  
and then incubated with 
RvD5n-3 DPA (0.001–10 nM) or 
vehicle (RPMI-1640 containing 
0.1% ethanol, 15 minutes, 37°C), 
after which (B and C) efferocy-
tosis of pHrodo Red–conjugated 
apoptotic HL-60 cells and (D 
and E) phagocytosis of pHrodo 
Green–conjugated S. aureus 
bioparticles were measured 
using a Zeiss Celldiscoverer 7 
high-content imager. B and 
D show the increase in signal 
over time for vehicle and 1 nM 
RvD5n-3 DPA groups, whereas 
C and E show the AUC for all 
tested concentrations. Results 
represent the mean ± SEM (n = 
6 donors from 2 distinct exper-
iments). *P < 0.05, **P < 0.01, 
and ***P < 0.001; 2-way ANOVA 
with Tukey’s post hoc multiple 
comparisons test. (F)  
Human monocyte–derived mac-
rophages were incubated with 
either an siRNA against GPR101 
or a control sequence and then 
with 10 nM RvD5n-3 DPA  
or vehicle (RPMI-1640 contain-
ing 0.1% ethanol; 2 hours at 
37°C), and the expression of 
l-kynurenine was measured 
using LC-MS/MS. Results 
represent the mean ± SEM (n = 
4 donors from 2 distinct exper-
iments). *P < 0.05; Friedman’s 
test with Dunn’s post hoc 
multiple comparisons test.
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trophils recruited to the peritoneum (5.6 ± 0.9 × 106 in vehicle- 
treated mice vs. 2.7 ± 0.7 × 106 cells per mouse in RvD5n-3 DPA–
treated mice) (Figure 8C); a significant upregulation in the ability 
of exudate neutrophils (1400 ± 118 MFI units in vehicle-treated 
mice vs. 1873 ± 150 MFI units in RvD5n-3 DPA–treated mice) and 
macrophages (3195 ± 94.7 MFI units in vehicle-treated mice vs. 
tration of RvD5n-3 DPA at a dose as low as 100 ng/mouse accelerat-
ed the resolution of E. coli–initiated inflammation, reducing the 
resolution interval (Ri) (i.e., the time it takes for neutrophil num-
bers to reduce from peak values to half maximum) from 26 hours 
to 16 hours (Figure 8B). This reduction in the resolution interval 
was linked with a significant reduction in the number of neu-
Figure 6. GPR101 mediates the pro-
tective actions of RvD5n-3 DPA on neu-
trophils and monocytes. (A–C) Human 
neutrophils were incubated with 
anti-GPR101 antibody or an isotype 
control antibody (15 minutes at room 
temperature) and then with RvD5n-3 DPA 
at the indicated concentrations or with 
vehicle (PBS containing 0.1% ethanol), 
and chemotaxis toward LTB4 (10 nM) 
was assessed using the xCELLigence 
DP system. (A) representative traces, 
(B) neutrophil chemotactic rate calcu-
lated from the slope of the curve, and 
(C) neutrophil chemotaxis calculated 
from the AUC of the traces shown 
in A. *P < 0.05 versus the indicated 
control group; Kruskal-Wallis test with 
Dunn’s post hoc multiple comparisons 
test. (D) Neutrophils were isolated and 
incubated as detailed above, and neu-
trophil–endothelial cell interactions 
were assessed after perfusing (0.1 Pa) 
neutrophils over an activated endothe-
lial cell monolayer. Results represent 
the mean ± SEM (n = 4 donors from 
3–4 distinct experiments). *P < 0.05 
and ***P < 0.001 versus the indicated 
control group; 2-way ANOVA with 
Sidak’s post hoc test. (E and F) Mice 
were administered 9 μg siRNA against 
mouse Gpr101 or a scrambled control 
sequence. After 72 hours, blood was 
collected and cells incubated with 
RvD5n-3 DPA (10 nM) or vehicle (20 
minutes at 37°C) and then with 5 × 107 
CFU fluorescently labeled bacteria (30 
minutes at 37°C), and phagocytosis in 
(E) neutrophils and (F) monocytes was 
assessed by flow cytometry. Results 
represent the mean ± SEM (n = 4 per 
group from 2 distinct experiments). 
**P < 0.01 versus the indicated control 
group; Kruskal-Wallis test with Dunn’s 
post hoc multiple comparisons test.
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vehicle-treated mice); and the IL-10R (195 ± 35 MFI units vs. 88 ± 
20 MFI units in RvD5n-3 DPA–treated mice vs. vehicle-treated mice) 
(Figure 8G and Supplemental Figure 6), markers associated with 
a homeostatic and resolution macrophage phenotype (25, 26). Of 
note, transfection of mice with an siRNA against mouse Gpr101, 
which led to a reduction in neutrophil and macrophage recep-
tor expression (Supplemental Figure 7), abolished the protective 
actions of RvD5n-3 DPA on both of these cell types (Figure 8, A–G, 
and Supplemental Figure 7). Together, these findings demonstrate 
that RvD5n-3 DPA activates host innate immune responses to pro-
mote the termination of infectious inflammation, actions that are 
mediated by GPR101.
Discussion
In the present study, using a screening approach, we identified 
GPR101 as a receptor for RvD5n-3 DPA. We found that RvD5n-3 DPA 
bound and activated GPR101 at a concentration that was com-
3965 ± 292 MFI units in RvD5n-3 DPA–treated mice) to take up bac-
teria (Figure 8, D and E); and macrophage efferocytosis (Figure 
8F). In these exudates, we also found a significant reduction in 
PGD2, PGE2 and the LTB4 metabolome, which encompasses the 
neutrophil chemoattractant LTB4 (Supplemental Figure 5).
Since macrophages are central players in both the termination 
and propagation of acute inflammation (4, 7, 18), we next inves-
tigated whether RvD5n-3 DPA regulates exudate macrophage phe-
notype during infectious inflammation. In exudate macrophages 
from mice given RvD5n-3 DPA and a control siRNA, we observed a 
decrease in the expression of MHC class II molecules (4863 ± 542 
MFI units vs. 9136 ± 1536 MFI units in RvD5n-3 DPA–treated mice vs. 
vehicle-treated mice). We observed an increase in the expression 
of the fractalkine receptor CX3CR1 (4010 ± 198 MFI units vs. 3160 
± 148 MFI units in RvD5n-3 DPA–treated mice vs. vehicle-treated 
mice); the lipid mediator biosynthetic enzyme COX-2 (994 ± 70 
MFI units vs. 1317 ± 106 MFI units in RvD5n-3 DPA–treated mice vs. 
Figure 7. Knockdown of GPR101 reverses 
the antiarthritic actions of RvD5n-3 DPA. 
Mice were administered 9 μg siRNA 
targeting mouse Gpr101 or a scrambled 
control sequence. After 24 hours and 72 
hours, mice were administered arthri-
togenic serum and then treated with 
RvD5n-3 DPA (150 ng/mouse) or vehicle (72 
hours and 96 hours after siRNA admin-
istration). (A) Clinical scores, (B) AUC for 
clinical scores, (C) weight loss, and (D) 
edema were determined throughout the 
disease process. (E and F) On day 7, hind 
paws were harvested and eicosanoid 
concentrations determined using LC-MS/
MS–based lipid mediator profiling. (E) 
Prostaglandin and (F) LTB4 metabolomic 
concentrations. Results represent the 
mean ± SEM (n = 4 mice per group). *P 
< 0.05 versus the vehicle-treated group; 
Kruskal-Wallis test with Dunn’s post hoc 
multiple comparisons test (B, E, and F) 
and 2-way ANOVA (C and D).
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GPR101 is an X-linked receptor expressed on chromosome 
Xq26.3, the longer arm of the X chromosome. The GPR101 gene 
encodes a 508-aa deduced protein that shares approximately 
30% sequence homology in the transmembrane regions with 
the α-1A-adrenergic receptor and the serotonin 5HT1A recep-
tor (https://www.omim.org/entry/300393#1). In human brain 
tissues, two GPR101 transcript variants have been identified, 
mensurate with its biological actions. Inhibition of GPR101 using 
anti-GPR101 antibodies and siRNA demonstrated a role for this 
receptor in mediating the immunoregulatory actions of RvD5n-3 DPA 
in both human and mouse leukocytes. Knockdown of Gpr101 in 
vivo reversed the joint protective actions of RvD5n-3 DPA during 
inflammatory arthritis and the pro-resolving actions of this medi-
ator during bacterial infections.
Figure 8. Gpr101 knockdown limits the ability of RvD5n-3 DPA to activate host responses to promote the resolution of E. coli infections. (A) Mice were inocu-
lated with 105 CFU E. coli via i.p. injection and lavages collected at the indicated time intervals before (0 hours) or after inoculation. RvD5n-3 DPA concentrations 
were determined using lipid mediator profiling. Results represent the mean ± SEM (n = 3 mice per group). (B) Mice were administered 9 μg siRNA against 
mouse Gpr101 or a scrambled control sequence, and after 72 hours, they were administered RvD5n-3 DPA (100 ng/mouse) or vehicle control (PBS containing 
0.1% ethanol) and then inoculated with 105 CFU E. coli via i.p. injection. (C) Fourteen-hour exudate neutrophil counts. Results represent the mean ± SEM  
(n = 6 mice per group from 2 distinct experiments). (D and E) Bacterial phagocytosis was determined in exudate (D) neutrophils and (E) macrophages at the 
14-hour interval using flow cytometry. (F) Efferocytosis was determined at the 14-hour interval in CD64+F4/80+ macrophages using flow cytometry. (G) The 
expression of MHC class II and IL-10R was assessed in CD64+F4/80+ macrophages using flow cytometry. Results represent the mean ± SEM (n = 6 mice per 
group from 2 distinct experiments). *P < 0.05 versus the vehicle-treated group; Kruskal-Wallis test with Dunn’s post hoc multiple comparisons test (C–G).
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reducing leukocyte infiltration into the paws (9). Here, we report 
that knockdown of GPR101 limited the protective actions of 
RvD5n-3 DPA in reducing joint and intestinal inflammation in exper-
imental inflammatory arthritis. Knockdown of this receptor also 
blunted the ability of RvD5n-3 DPA to reduce the levels of inflamma-
tory eicosanoids in the gut and joints of arthritic mice as well as 
promote the upregulation of SPMs in arthritic mice.
Bacterial infections result from an inability of the host 
immune response to contain invading pathogens (1). The pre-
vailing approach to treating infections is to inhibit bacterial rep-
lication using antibiotics. The recent rise in antibiotic-resistant 
bacteria has spurred the search for novel approaches to treat 
infections. Studies investigating endogenous mechanisms pro-
moting the resolution of bacterial infections demonstrate that 
SPMs reprogram the host immune response to positively regu-
late the uptake and killing of bacteria (4). Indeed, we found here 
that RvD5n-3 DPA promoted the uptake of bacteria by neutrophils, 
monocytes, and macrophages in a GPR101-dependent manner. 
Administration of RvD5n-3 DPA to mice also reduced the exudate 
concentrations of inflammatory eicosanoids, neutrophil infil-
tration into the site of inflammation, and the resolution inter-
val from 26 hours to 16 hours. Of note, knockdown of GPR101 
reversed these protective actions, underscoring the role of SPMs 
in reprogramming host immune responses during infection and 
the role of GPR101 in mediating the immunomodulatory actions 
of RvD5n-3 DPA during infections.
In summary, we have identified an immunoregulatory axis 
centered on GPR101/RvD5n-3 DPA that promotes the termination of 
both sterile and infectious inflammation. These findings demon-
strate that GPR101 is the conveyor for the immune-regulatory 
properties of RvD5n-3 DPA and establish a role for this receptor in 
mediating the regulation of joint inflammation, both locally and 
remotely through the gut barrier, and in instructing the host to 
efficiently dispose of bacterial pathogens. Thus, these results 
provide new cues for harnessing the immune-modulatory actions 
of pro-resolving mediators by developing innovative therapeutic 
approaches based on the RvD5n-3 DPA/GPR101 axis.
Methods
GPCR screening
Using PathHunter β-arrestin enzyme fragment complementation 
(EFC) technology coupled with β-gal (DiscoveRx), we screened 49 
orphan receptors. GPCR screening was performed by incubating 10 nM 
RvD5n-3 DPA or vehicle control (PBS in 0.01% ethanol) at 37°C for 90 
minutes with the candidate GPCRs, and receptor activation was deter-
mined by measuring the luminescence signal. Negative controls were 
used to measure the potential constitutive activity in the absence of 
ligand. This custom screening was performed in duplicate, and the mean 
chemiluminescence value was used for analysis. The percentage of 
activity was calculated using the following formula: percentage of activ-
ity = 100% × (mean relative luminescence units [RLU] of the test sample 
– mean RLU of the vehicle control)/(mean RLU of the vehicle control).
GPCR–β-arrestin assays
To monitor downstream receptor activation, the β-arrestin Path-
Hunter system (DiscoveRx) was used. CHO cells stably express-
one of 9.5 kb and the second of 4.2 kb, whereas in mouse brain, 
a 5.5-kb transcript was identified. The human GPR101 protein 
shares approximately 71% identity with the deduced mouse pro-
tein, which is predicted to be 511 aa in size. In the present study, 
we demonstrate that this receptor was expressed on human and 
mouse neutrophils, monocytes, and macrophages (Figure 1 and 
Supplemental Figures 2, 3, and 7). In humans, several mutations 
have been identified for this receptor that include the E308D 
mutation, which was identified in tumour DNA (27). A second 
mutation, the substitution of D366E, was identified in a patient 
with sporadic acromegaly (28). However, the functional impact of 
these mutations is not well characterized, given that the endoge-
nous ligand(s) for this receptor were not known.
Pro-resolving mediators exert potent actions in the regulation 
of innate immune responses. These biological actions are medi-
ated via activation of select GPCRs, to which these molecules 
bind with high stereospecificity and affinity (14–18). In the present 
study, using radiolabeled RvD5n-3 DPA, we found that this media-
tor bound to GPR101 with a KD of approximately 6.9 nM, which 
is comparable to its bioactive concentration range. We also found 
that RvD5n-3 DPA at concentrations as low as 0.1–10 nM was able to 
activate the receptor. This ability to activate intracellular signal-
ing was found to be stereospecific, since neither RvD1n-3 DPA nor 
PD1n-3 DPA elicited marked changes in luminescence or impedance 
in GPR101-transfected CHO cells. Furthermore, subtle changes to 
the chemical backbone such as the substitution of the double bond 
at C10 and C13 for triple bond, which increases the rigidity of the 
molecule, also led to a significant (P < 0.5) decrease in its ability to 
activate the receptor.
Flow cytometric analysis revealed that GPR101 was expressed 
on both human and mouse neutrophils, monocytes, and macro-
phages. Leukocytes are involved in the initiation and termination 
of both sterile and inflammatory responses, with neutrophils, 
monocytes, and macrophages being the first responders (1, 2, 
6, 7, 9, 18). SPMs, including RvD5n-3 DPA, have leukocyte-directed 
actions that regulate leukocyte trafficking to the site of inflam-
mation (4, 8, 10, 18), promoting the uptake and killing of bacteria 
and enhancing the clearance of apoptotic cells and cellular debris. 
Results from the present studies demonstrate that knockdown 
of GPR101 limited the ability of human macrophages to take 
up both apoptotic cells and bacteria in response to RvD5n-3 DPA. 
Furthermore, inhibition of the receptor on human neutrophils 
using an anti-GPR101 antibody limited the biological actions of 
RvD5n-3 DPA, thereby reducing the ability of this mediator to pro-
mote the uptake and killing of bacteria, reversing its antichemo-
tactic actions on neutrophils, and limiting its ability to reduced 
neutrophil diapedesis.
Rheumatoid arthritis is an autoimmune disease perpetuated 
by unremitting joint inflammation that results in bone destruc-
tion and joint deformation (29). Neutrophils and monocytes are 
implicated in the propagation of the effector phase of the disease. 
In a recent study by our group, we found that, in addition to joint 
inflammation, inflammatory arthritis also led to gut inflamma-
tion and weakening of the gut barrier, an observation that was 
linked with a reduction in intestinal levels of RvD5n-3 DPA (11). Fur-
thermore, administration of RvD5n-3 DPA to arthritic mice reduced 
both joint and gut inflammation, restoring barrier function and 
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then with or without 10 μM RvD5n-3 DPA for 60 minutes at 4°C. Cells 
were then transferred onto Whatman GF/C glass microfiber filters, 
and unbound ligand was removed by washing twice with 4 mL ice-cold 
DPBS using a vacuum manifold (MilliporeSigma). Bound radioactivity 
was determined using a scintillation counter (Beckman Coulter).
GPCR expression on primary cells
Human leukocyte GPCR expression. Expression of GPR101, GPR12 
(host: rabbit, lot AG11012912, catalog bs-13514R, Bioss) and GPR84 
(host: mouse, lot 08248 WECz, catalog H00053831-A01, Abnova) 
was assessed in human peripheral blood monocytes, neutrophils, and 
macrophages. Nonspecific binding was quenched using FC block-
ing solution. Human cells were incubated with rabbit anti–human 
GPR101, rabbit anti–human GPR12, or mouse anti–human GPR84 
(30 minutes at 4°C) and then with AF488-conjugated goat anti–rabbit 
IgG (Thermo Fisher Scientific) or AF488-conjugated goat anti–mouse 
IgG (Thermo Fisher Scientific) for 30 minutes at 4°C. Cells were then 
incubated with AF647-conjugated anti–human CD14 (clone HCD14, 
BioLegend) and APC-Cy7–conjugated anti–human CD16 (clone 3G8, 
BioLegend; for monocytes) antibodies (30 minutes at 4°C). For whole 
blood incubation, RBCs were lysed using a BD Pharmingen Red Blood 
Cell Lysis Kit following the manufacturer’s instructions, and fluores-
cence staining was evaluated using an LSR Fortessa Cell Analyzer (BD 
Biosciences) and FlowJo software, version 10 (Tree Star).
Mouse leukocyte GPCR expression. Peripheral blood was collected 
via cardiac puncture in 3.2 % sodium citrate. Cells were then incu-
bated with anti–mouse CD16/CD32 (clone 93, eBioscience; dilution 
1:100, 20 minutes at 4°C in PBS containing 5% FCS staining solu-
tion). Peripheral blood cells were then incubated with AF700-conju-
gated anti–mouse Ly6G (clone 1A8, BioLegend; for neutrophils) and 
BV421-conjugated anti–mouse CD115 (clone AFS98, BioLegend; for 
monocytes) antibodies (30 minutes at 4°C), and receptor expression 
was evaluated as described above.
Targeted lipid mediator profiling
Paws and intestinal tissues were collected and immediately trans-
ferred to liquid nitrogen prior to homogenization in 1 mL ice-cold 
MeOH using a glass dounce. All samples for LC-MS/MS–based profil-
ing were extracted using solid-phase extraction columns as described 
previously (30). Prior to sample extraction, deuterated internal stan-
dards, representing each region in the chromatographic analysis (500 
pg each) were added to facilitate quantification. Samples were kept at 
–20°C for a minimum of 45 minutes to allow for protein precipitation. 
Supernatants were subjected to solid-phase extraction, and the methyl 
formate fraction was collected, brought to dryness, and suspended 
in phase (methanol/water, 1:1, vol/vol) for injection on a Shimadzu 
LC-20AD HPLC and a Shimadzu SIL-20AC autoinjector, paired with 
a QTrap 6500 Plus (Sciex). An Agilent Poroshell 120 EC-C18 column 
(100 mm × 4.6 mm × 2.7 μm) was kept at 50°C and the mediators 
eluted using a mobile phase consisting of methanol/water/acetic acid 
ratio of 20:80:0.01 (vol/vol/vol) that was ramped to 50:50:0.01 (vol/
vol/vol) over 0.5 minutes and then to 80:20:0.01 (vol/vol/vol) from 2 
minutes to 11 minutes, maintained until 14.5 minutes, and then rapidly 
ramped to 98:2:0.01 (vol/vol/vol) for the next 0.1 minutes. This was 
subsequently maintained at 98:2:0.01 (vol/vol/vol) for 5.4 minutes, 
and the flow rate was maintained at 0.5 mL/min. QTrap 6500 Plus 
was operated using a multiple reaction monitoring method as previ-
ing human recombinant GPR12, GPR84, or GPR101 coupled to a 
β-arrestin reporter system were cultured in media containing 10% 
heat-inactivated FBS. GPCR and β-arrestin expression was main-
tained by dual selection in hygromycin B and geneticin according to 
the manufacturer’s instructions (DiscoveRx). For the experiments, 
single-use (eXpress) CHO cells stably expressing human recombinant 
GPR18 or GPR32 coupled to a β-arrestin reporter system were used. 
For all GPCR–β-arrestin assays, cells were plated in 96-well plates 48 
hours before experiments using AssayComplete Cell Plating Reagent 
(DiscoveRx). Cells were incubated with the indicated concentrations of 
RvD5n-3 DPA (Vinresol, custom synthesis), PD1n-3 DPA, or RvD1n-3 DPA (pro-
vided by Trond Vidar Hansen, University of Oslo, Oslo, Norway) for 
1 hour at 37°C, and receptor activation was determined by measuring 
chemiluminescence using the PathHunter Detection Kit (DiscoveRx).
xCELLigence RTCA DP system
Ligand-receptor interactions were assessed by monitoring impedance 
changes across single-cell monolayers using an xCELLigence DP Sys-
tem (ACEA Biosciences). GPR101-overexpressing CHO cells were 
plated on electronic microtiter plates (E-Plates). Test compounds were 
added to the chambers in serum-free medium, and real-time imped-
ance changes were monitored (0–30 minutes at 37°C). For antibody 
incubations, anti-GPR101 antibody (clone G278, host: rabbit, Assay 
Biotechnology) or nonimmune rabbit IgG was incubated with cells on 
microtiter plates at 1:50 dilutions for 20 minutes before addition of 
the indicated mediators. In select experiments, GPR101-overexpress-
ing CHO cells were incubated with CTX (1 μg/mL, 2 hours), PTX (1 
μg/mL, 16 hours), or vehicle. Cells were then washed with serum-free 
HAM F-12 serum-free medium. RvD5n-3 DPA (10 nM) was added and 
impedance changes were assessed over a 30-minute period.
Preparation of [10, 11, 13, 143H]-RvD5n-3 DPA and radioligand binding
Total organic synthesis of [10, 11, 13,143H]-RvD5n-3 DPA was done by 
Vinresol (custom synthesis) via the tritiation of (7S,8E,15E,17S,19Z)-7,17- 
dihydroxydocosa-8,15,19-trien-10,13-diynoate. The integrity and activ-
ity of the radioligand was ascertained using reverse-phase UV-HPLC 
(RV-UV-HPLC) system (1100 Series, Agilent Technologies) equipped 
with an Eclipse Plus C18 Column (100 mm × 4.6 mm × 1.8 μm; Agilent 
Technologies) coupled with a diode array detector (DAD) (G1315B; Agi-
lent Technologies). A gradient of methanol/water of 55:45 (vol/vol) was 
ramped to 63:37 (vol/vol) over a 22-minute period and then to 98:2 (vol/
vol) for the next 8 minutes. The flow rate was maintained at 0.5 mL/min.
To assess the affinity of the radioligand for human GPR101, 
GPR101-overxpressing CHO cells were suspended in DPBS con-
taining Ca2+ and Mg2+. For competition binding experiments, 0.5 
× 106 cells/0.1 mL were incubated with approximately 3 nM [10, 11, 
13,143H]-RvD5n-3 DPA (specific activity ~40 Ci/mmol) in the absence 
or presence of increasing concentrations of unlabeled RvD5n-3 DPA (1 
nM–10 μM). Following incubation for 60 minutes at 4°C, cells were 
transferred to Whatman GF/C glass microfiber filters (Thermo Fisher 
Scientific), and unbound ligand was removed by washing twice with 
4 mL ice-cold Dulbecco’s PBS (DPBS) using a vacuum manifold (Mil-
liporeSigma). Bound radioactivity was then determined using a scin-
tillation counter (Beckman Coulter). Nonspecific binding was deter-
mined in the presence of 10 μM unlabeled RvD5n-3 DPA.
For saturation binding experiments, 0.5 × 106 cells/0.1 mL cells 
were incubated with [10, 11, 13,143H]-RvD5n-3 DPA (1.25–100 nM), and 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 7 1jci.org   Volume 130   Number 1   January 2020
24 hours, mice were i.p. administered 100 μl K/BxN serum (provid-
ed by Mauro Perretti and Dianne Cooper, Queen Mary University of 
London, London, United Kingdom) on days 0 and 2 to initiate inflam-
matory arthritis. Clinical scores were monitored daily using a 26-point 
arthritic scoring system (11). Mouse ankles, wrists, pads, and digits were 
inspected daily for swelling and redness. Blood, paws, and intestines 
were collected on day 8.
Mouse peripheral blood leukocyte phagocytosis. Six- to eight-week-
old male C57BL/6 mice (Charles River Laboratories; the supplier fed 
the mice a lab diet containing essential fatty acids) were i.p. admin-
istered 8 μg Accell Control siRNA or Accell Mouse GPR101 siRNA 
SMARTpool (Dharmacon). After 3 days, blood was collected via car-
diac puncture and incubated with either RvD5n-3 DPA (10 nM) or vehicle 
(PBS containing 0.1% ethanol) for 20 minutes at 37°C, and then with 
5 × 107 CFU fluorescently labeled E. coli for 60 minutes at 37°C. At the 
end of the incubations, RBCs were lysed using a BD Pharmingen Red 
Blood Cell Lysis Kit following the manufacturer’s instructions. The 
cells were then fixed and incubated with anti-CD16/CD32 antibody 
(20 minutes at 4°C) followed by AF700-conjugated anti–mouse Ly6G 
(clone 1A8, BioLegend; for neutrophils) and BV-421–conjugated anti–
mouse CD115 (clone AFS98, BioLegend; for monocytes) antibodies 
(30 minutes at 4°C). Cells were then washed and staining evaluated 
using a BD Fortessa II with BD FACSDiva software, and the results 
were analyzed using FlowJo software, version 10.4 (Tree Star).
Blood collection from healthy volunteers
Venous peripheral blood was collected at the indicated intervals in 
sodium citrate (3.2%) from fasting volunteers who declared they had 
not taken NSAIDS for at least 14 days or consumed caffeine or alcohol 
for at least 24 hours or fatty fish for at least 48 hours.
Human neutrophil responses
Human neutrophil chemotaxis. Human peripheral blood neutrophils 
were isolated from healthy volunteers as detailed above. Cells were 
incubated with either an antibody against GPR101 or an isotype con-
trol for 15 minutes at room temperature and then with RvD5n-3 DPA 
(0.1–10 nM) or vehicle control (PBS containing 0.01% ethanol) for 15 
minutes at 37°C. Neutrophils were then transferred to the top chamber 
of a preloaded cell invasion and migration plate (CIM-Plate 16) on an 
xCELLigence DP system, and chemotaxis toward LTB4 (10 nM) was 
assessed in real time for 30 minutes.
Human neutrophil–endothelial cell interactions. Human neutro-
phils, isolated as detailed above, were incubated with either an anti-
body against GPR101 or an isotype control for 15 minutes at room tem-
perature and then with RvD5n-3 DPA (0.1–10 nM) or vehicle control (PBS 
containing 0.01% ethanol) for 15 minutes at 37°C. Cells were then 
perfused over TNF-α–activated human umbilical endothelial cells (10 
ng/mL, 4 hours) at 0.1 PA for 8 minutes, 6 random 10-second fields 
were recorded per condition, and neutrophil–endothelial cell interac-
tions were quantified as previously described (4).
Human macrophage responses
Human monocyte–derived macrophage efferocytosis. PBMCs from healthy 
volunteers were purchased from the NHS Blood and Transplant Bank. 
PBMCs were isolated using Histopaque 1077 (MilliporeSigma) density 
centrifugation from blood cones. Macrophages were prepared using 
previously published protocols (31). Briefly, PBMCs were plated onto 
ously described (30). Each lipid mediator was identified using estab-
lished criteria including matching of the retention time to synthetic 
or authentic standards and at least 6 diagnostic ions (30). Calibration 
curves were obtained for each mediator using lipid mediator mixtures 
at 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 200 pg that gave linear 
calibration curves with r2 values of 0.98–0.99.
Animal experiments
E. coli peritonitis. Six- to eight-week-old male C57BL/6 mice (Charles 
River Laboratories, the supplier fed the mice a lab diet containing 
essential fatty acids) were administered 9 μg Accell Control siRNA 
or Accell Mouse GPR101 siRNA SMARTpool (Dharmacon) via i.p. 
injection. After 3 days, mice were administered RvD5n-3 DPA (100 ng/
mouse) or vehicle via i.p. injection immediately prior to i.p. injection 
of live E. coli (serotype O6:K2:H1, 105 CFU per mouse). At designated 
time intervals, the mice were euthanized, blood was collected via 
cardiac puncture in sodium citrate, and peritoneal exudates were 
collected in 4 mL PBS.
The cellular composition in the exudates was determined using 
Turk’s solution, light microscopy, and flow cytometry. For the latter, 
exudate cells were incubated with anti–mouse CD16/CD32 (clone 93, 
eBioscience; dilution 1:100, 20 minutes at 4°C in PBS containing 5% 
FCS staining solution), followed by incubation with phycoerythrin (PE) 
CD64 (FcγRI, clone X54-5/7.1, host mouse, BioLegend), Alexa Fluor 
700 Ly-6G (clone 1A, host rat, BioLegend), Brilliant Violet 711 CD115 
(CSF-1R) (clone AFS98, host rat, BioLegend), Brilliant Violet 510 CD43 
(clone 1G10, host mouse, BD Biosciences), and APC/cyanine7 F4/80 
(clone BM8, host rat, BioLegend) for 45 minutes on ice. To assess bac-
terial phagocytosis in peritoneal exudate leukocytes, exudate cells 
were incubated with anti–mouse CD16/CD32 (clone 93, eBioscience; 
dilution 1:100, 20 minutes at 4°C in PBS containing 5% FCS staining 
solution) and then with Alexa Fluor 700–conjugated anti–mouse Ly6G 
(for neutrophils), APC/Cy7-conjugated anti–mouse F4/80, and PE- 
conjugated anti–mouse CD64 antibodies (monocyte-derived macro-
phages; 30 minutes at 4°C in staining solution). Cells were then fixed 
and permeabilized using BD Perm/Wash Buffer (BD Biosciences) 
following the manufacturer’s instructions and incubated with FITC- 
conjugated anti–E. coli antibody (catalog GTX13626, GenTex; 1:50 
dilution, 30 minutes at 4°C in BD Perm/Wash Buffer).
We assessed efferocytosis in infectious exudates by incubating 
exudate leukocytes with anti–mouse CD16 and anti–mouse CD32 
and then with APC- and Cy7-conjugated anti–mouse F4/80 and 
PE-conjugated anti–mouse CD64 antibodies (30 minutes at 4°C in 
staining solution). Cells were then fixed and permeabilized using 
BD Perm/Wash Buffer (BD Biosciences) and incubated with FITC- 
conjugated anti–mouse Ly6G antibody (30 minutes at 4°C, in BD 
Perm/Wash Buffer).
In select experiments, resolution indices were calculated as 
described previously (17, 18), where the time difference for neutrophil 
numbers to go from maximum to half maximum was determined as 
the Ri. To assess the pro-resolving actions of the test products, these 
products were administered 12 hours after E. coli (105 CFU) inocula-
tion, and resolution indices were assessed.
Inflammatory arthritis. Ten-week-old male C57BL/6 mice (Charles 
River Laboratories, the supplier fed the mice a lab diet containing essen-
tial fatty acids) were administered 9 μg Accell Control siRNA or Accell 
Mouse GPR101 siRNA SmartPool (Dharmacon) via i.p. injection. After 
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FBS. Cells were then incubated with 10 nM RvD5n-3 DPA or vehicle. Two 
hours later, cells were collected using methanol containing deuterium- 
labeled choline and subjected to LC-MS/MS analysis as detailed previ-
ously (11) to determine l-kynurenine concentrations.
Statistical analysis
We performed all statistical analyses and data derivation using Graph-
Pad Prism 8 (GraphPad Software) and Microsoft Excel software. 
Results presented in the figures are expressed as the mean ± SEM. Sta-
tistical differences between groups were determined as described in 
the figure legends. Briefly, Gaussian distribution of the data was test-
ed using the Shapiro-Wilk normality test. For data following a normal 
distribution, statistical differences were tested using 1-way or 2-way 
ANOVA with a Holm-Sidak or Tukey’s post hoc multiple comparisons 
tests. For data not following a normal distribution, a Kruskal-Wallis 
test with Dunn’s post hoc multiple comparisons test was used. Sample 
sizes for each experiment were determined on the basis of the variabil-
ity observed in prior experiments.
Study approval
Animal experiments were approved by the United Kingdom Home 
Office, London, United Kingdom (P998AB295) and adhered to the 
Guidance on the Operation of Animals, Scientific Procedures Act 
and to Laboratory Animal Science Association Guidelines (Guiding 
Principles on Good Practice for Animal Welfare and Ethical Review Bod-
ies, Royal Society for the Prevention of Cruelty to Animals [RSPCA], 
2015). Studies involving human primary cells were approved by the 
Queen Mary Research Ethics Committee, London, United Kingdom 
(QMREC 2014:61). All volunteers provided informed consent before 
blood donation. Healthy volunteers who donated blood gave written 
consent in accordance with a Queen Mary Research Ethics Committee 
(QMREC 2014:61) and Declaration of Helsinki principles.
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10-cm tissue culture plates and incubated at 37°C for 30 minutes in PBS 
containing calcium and magnesium. Subsequently, cells were washed 
using PBS without calcium and magnesium, and adherent cells were 
incubated in RPMI 1640 containing 10% human serum and 20 ng/mL 
granulocyte macrophage–CSF (GM-CSF) for 7 days at 37°C in 5% CO2.
On day 7, monocyte-derived macrophages were then seeded 
onto 96-well plates at 4 × 104 cells per well and transfected with 1 
μM Accell Human Control siRNA or Accell Anti–human GPR101  
siRNA SMARTpool for 72 hours in serum-free Accell siRNA Delivery 
Medium (Dharmacon). Apoptotic target cells for efferocytosis were 
generated as follows: human promyelocytic HL-60 cells were seeded 
at 1 × 106 cells/mL onto 35-mm plates, irradiated with UV-C light 
(254 nm) for 15 minutes, and incubated at 37°C for 2 hours. Apoptosis 
induction was verified by flow cytometry using the APC Annexin V 
Apoptosis Detection Kit with PI (BioLegend), in which annexin V–pos-
itive and annexin V/PI–double-positive cells were considered to be 
apoptotic. Apoptotic HL-60 cells were washed with PBS and labeled 
with 1 μM pHrodo Red Succinimidyl Ester (Invitrogen, Thermo 
Fisher Scientific) in PBS for 30 minutes at room temperature. Macro-
phages were stained with CellBrite Blue (Biotium) for 1 hour at 37°C 
to visualize cell membranes, washed with RPMI-1640, and incubated 
with RvD5n-3 DPA (0.001–10 nM) or vehicle (RPMI-1640 containing 
0.1% ethanol) for 15 minutes at 37°C. Apoptotic pHrodo Red–labeled 
HL-60 cells were added directly to the macrophages at a 3:1 ratio 
(apoptotic HL-60/macrophage), and the increase in pHrodo Red 
signal over time (representing apoptotic cell efferocytosis by macro-
phages) was quantified using a Zeiss Celldiscoverer 7 high-content 
imaging system.
Human monocyte–derived macrophage phagocytosis. Monocyte- 
derived macrophages were seeded onto 96-well plates at 4 × 104 cells 
per well and transfected with 1 μM Accell Human Control siRNA or 
Accell Anti–human GPR101 siRNA SMARTpool for 72 hours in serum-
free Accell siRNA Delivery Medium (Dharmacon). Macrophages were 
stained with Hoechst 33342 (Thermo Fisher Scientific) for 1 hour at 
37°C to visualize cell nuclei, washed with RPMI-1640, and incubated 
with RvD5n-3 DPA (0.001–10 nM) or vehicle (RPMI-1640 containing 
0.1% ethanol) for 15 minutes at 37°C. pHrodo Green–labeled S. aureus 
bioparticle conjugates (Invitrogen, Thermo Fisher Scientific) were 
opsonized by incubation in PBS containing 20% (v/v) human serum. 
Opsonized pHrodo Green–labeled S. aureus bioparticles were directly 
added to the macrophages at a final concentration of 5 μg per well, and 
the increase in pHrodo Green signal over time (representing phago-
cytosis of bacterial particles by macrophages) was quantified using a 
Zeiss Celldiscoverer 7 high-content imaging system.
cAMP measurements. Human monocyte–derived macrophages 
were seeded onto 12-well plates at 5 × 105 cells per well and then 
transfected with 1 μM Accell Human Control siRNA or Accell 
Anti–human GPR101 siRNA SMARTpool for 72 hours in serum-free 
Accell siRNA Delivery Medium (Dharmacon). Cells were incubated 
with RvD5n-3 DPA (1 nM) or vehicle (PBS containing 0.01% ethanol) for 
2 minutes, after which incubations were quenched with 5% Triton 
X-100, cells were homogenized, and cAMP levels were determined 
by ELISA following the manufacturer’s instruction (Elite cAMP 
ELISA Assay kit, eEnzyme).
Monocyte-derived macrophage l-kynurenine. Macrophages were 
prepared as detailed above and then seeded onto 12-well plates at 2.5 
× 105 cells per well and kept overnight in RPMI 1640 containing 10% 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 7 3jci.org   Volume 130   Number 1   January 2020
 1. Majno G. The ancient riddle of sigma eta psi iota 
sigma (sepsis). J Infect Dis. 1991;163(5):937–945.
 2. Malagoli D. The evolution of the immune system: 
conservation and diversification. Cambridge, Mas-
sachusetts, USA: Academic Press; 2016.
 3. Scapini P, Cassatella MA. Location in the spleen 
dictates the function of murine neutrophils. J Exp 
Med. 2017;214(5):1207–1209.
 4. Spite M, et al. Resolvin D2 is a potent regulator of 
leukocytes and controls microbial sepsis. Nature. 
2009;461(7268):1287–1291.
 5. Quiros M, et al. Macrophage-derived IL-10  
mediates mucosal repair by epithelial WISP-1  
signaling. J Clin Invest. 2017;127(9):3510–3520.
 6. Sumagin R, et al. Neutrophil interactions with 
epithelial-expressed ICAM-1 enhances intesti-
nal mucosal wound healing. Mucosal Immunol. 
2016;9(5):1151–1162.
 7. Dalli J, Serhan CN. Pro-resolving mediators in 
regulating and conferring macrophage function. 
Front Immunol. 2017;8:1400.
 8. Hellmann J, et al. Biosynthesis of D-series  
resolvins in skin provides insights into 
their role in tissue repair. J Invest Dermatol. 
2018;138(9):2051–2060.
 9. Colas RA, et al. Impaired production and diurnal 
regulation of vascular RvDn-3 DPA increase systemic 
inflammation and cardiovascular disease. Circ 
Res. 2018;122(6):855–863.
 10. Dalli J, Colas RA, Serhan CN. Novel n-3 immuno-
resolvents: structures and actions. Sci Rep. 
2013;3:1940.
 11. Flak MB, Colas RA, Muñoz-Atienza E, Curtis MA, 
Dalli J, Pitzalis C. Inflammatory arthritis disrupts 
gut resolution mechanisms, promoting barrier 
breakdown by Porphyromonas gingivalis. JCI 
Insight. 2019;4(13):125191.
 12. Dalli J, Serhan CN. Identification and structure 
elucidation of the pro-resolving mediators pro-
vides novel leads for resolution pharmacology.  
Br J Pharmacol. 2019;176(8):1024–1037.
 13. Sugimoto Y, Narumiya S. Prostaglandin E recep-
tors. J Biol Chem. 2007;282(16):11613–11617.
 14. Fiore S, Romano M, Reardon EM, Serhan CN. 
Induction of functional lipoxin A4 receptors in 
HL-60 cells. Blood. 1993;81(12):3395–3403.
 15. Perretti M, et al. Endogenous lipid- and peptide- 
derived anti-inflammatory pathways generated  
with glucocorticoid and aspirin treatment 
activate the lipoxin A4 receptor. Nat Med. 
2002;8(11):1296–1302.
 16. Krishnamoorthy S, et al. Resolvin D1 binds 
human phagocytes with evidence for prore-
solving receptors. Proc Natl Acad Sci U S A. 
2010;107(4):1660–1665.
 17. Dalli J, et al. Resolvin D3 and aspirin-triggered 
resolvin D3 are potent immunoresolvents.  
Chem Biol. 2013;20(2):188–201.
 18. Chiang N, Dalli J, Colas RA, Serhan CN.  
Identification of resolvin D2 receptor mediating  
resolution of infections and organ protection.  
J Exp Med. 2015;212(8):1203–1217.
 19. Olson KR, Eglen RM. Beta galactosidase comple-
mentation: a cell-based luminescent assay plat-
form for drug discovery. Assay Drug Dev Technol. 
2007;5(1):137–144.
 20. Peters MF, Scott CW. Evaluating cellular imped-
ance assays for detection of GPCR pleiotropic 
signaling and functional selectivity. J Biomol 
Screen. 2009;14(3):246–255.
 21. Gerlach BD, et al. Resolvin D1 promotes the tar-
geting and clearance of necroptotic cells [pub-
lished online ahead of print June 20, 2019]. 
Cell Death Differ. https://doi.org/10.1038/
s41418-019-0370-1.
 22. Lanis JM, et al. Tryptophan metabolite activation 
of the aryl hydrocarbon receptor regulates IL-10 
receptor expression on intestinal epithelia. Muco-
sal Immunol. 2017;10(5):1133–1144.
 23. Gobbetti T, et al. Protectin D1n-3 DPA and resolvin 
D5n-3 DPA are effectors of intestinal protection. 
Proc Natl Acad Sci USA. 2017;114(15):3963–3968.
 24. Christensen AD, Haase C, Cook AD, Hamilton 
JA. K/BxN serum-transfer arthritis as a model for 
human inflammatory arthritis. Front Immunol. 
2016;7:213.
 25. Yang W, et al. Neutrophils promote the develop-
ment of reparative macrophages mediated by 
ROS to orchestrate liver repair. Nat Commun. 
2019;10(1):1076.
 26. Zigmond E, et al. Macrophage-restricted inter-
leukin-10 receptor deficiency, but not IL-10 
deficiency, causes severe spontaneous colitis. 
Immunity. 2014;40(5):720–733.
 27. Trivellin G, et al. Gigantism and acromegaly due 
to Xq26 microduplications and GPR101 muta-
tion. N Engl J Med. 2014;371(25):2363–2374.
 28. Kamenický P, Bouligand J, Chanson P. Gigantism, 
acromegaly, and GPR101 mutations. N Engl J 
Med. 2015;372(13):1264–1265.
 29. Pitzalis C, Kelly S, Humby F. New learnings on 
the pathophysiology of RA from synovial biop-
sies. Curr Opin Rheumatol. 2013;25(3):334–344.
 30. Walker ME, Souza PR, Colas RA, Dalli J. 13-Series 
resolvins mediate the leukocyte-platelet actions 
of atorvastatin and pravastatin in inflammatory 
arthritis. FASEB J. 2017;31(8):3636–3648.
 31. Dalli J, Serhan CN. Specific lipid mediator sig-
natures of human phagocytes: microparticles 
stimulate macrophage efferocytosis and pro-re-
solving mediators. Blood. 2012;120(15):e60–e72.
